Kentucky is currently home to 1039 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Combination Therapy for Recurrent Ovarian Cancer
NCT05610735
Recruiting
The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study contains two parts. In part 1 (phase I), 18 patients with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tab... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UofL Health Brown Cancer Center, Louisville, Kentucky
Conditions: Recurrent Ovarian Cancer
Register for Updates
Facing Eating Disorder Fears for Anorexia Nervosa
NCT05596799
Recruiting
FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment tar... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Eating Anxiety Laboratory and Clinic, Louisville, Kentucky
Conditions: Eating Disorders, Anorexia Nervosa, Anorexia Nervosa in Remission
Register for Updates
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
NCT05576350
Recruiting
Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit "ri... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/25/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Risk Behavior, Alcohol Use Disorder, HIV Infections
Register for Updates
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652
Recruiting
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/25/2025
Locations: University of Kentucky Markey Cancer Center, Lexington, Kentucky
Conditions: Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Register for Updates
Blood Flow Restriction Training After Patellar INStability
NCT04554212
Recruiting
This research study is designed to allow health care professionals and researchers to answer many questions about whether a new type of physical therapy called blood flow restriction training (called BFRT) will improve recovery for those with patellar instability.
Gender:
ALL
Ages:
Between 14 years and 40 years
Trial Updated:
03/25/2025
Locations: UK Healthcare at Turfland, Lexington, Kentucky
Conditions: Patellar Dislocation, Knee Injuries, Leg Injury, Wounds and Injuries
Register for Updates
Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH
NCT06830980
Recruiting
The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: UK Department of Psychiatry, Lexington, Kentucky
Conditions: Methamphetamine Use Disorders, HIV
Register for Updates
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
NCT06683365
Recruiting
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed in... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
03/24/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Multiple System Atrophy, Parkinsons Disease
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Cystic Fibrosis
Register for Updates
Chronic Nausea and Vomiting in Patients with Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926
Recruiting
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Nausea, Vomiting
Register for Updates
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139
Recruiting
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Markey Cancer Center / University of Kentucky, Lexington, Kentucky
Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: Research Site, Louisville, Kentucky
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03484299
Recruiting
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Pancreas Cancer
Register for Updates